Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > ORGANIZATION
ORGANIZATION
- BMS Exec Ohura Appointed as CEO of GHIT Fund
March 29, 2019
- JPMA Poised to Continue Pitching Drugs’ Multi-Faceted Values to Politicians: Director General
March 25, 2019
- 2020 Drug Price Revision Is Focus Issue for FPMAJ in FY2019 Plan
March 25, 2019
- FPMAJ Wants Asian Equivalent of EMA, Chairman Stresses Merit of Blanket Approval
March 20, 2019
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads
March 13, 2019
- Look at Societal Values of Medicines in Pricing: Japan Pharma Industry Chief
March 12, 2019
- Japan Has High Market Access Barriers, Revised PMP Could Stymie Innovation: US Chamber of Commerce Official
March 7, 2019
- Biotech Execs Raise Alarm over Price Maintenance Criteria, CEA Introduction: BIO Asia Confab
March 6, 2019
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
- Sanofi CEO Becomes Chairman of PhRMA
February 6, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
- JPMA Lays Out Policy Proposal 2019, Advocates Pricing Premium for Drugs Used for Pregnant Women
January 25, 2019
- Think Tank Urges Govt to Look at Drugs with Large Prescription Volumes Too
January 25, 2019
- Regional Formulary Initiatives Underway, Eyes on Cost Control for Branded Drugs with No Gx
January 22, 2019
- Don’t Cause Disruptions in Drug Distribution with October Re-Pricing: Japan Wholesaler Chief
January 15, 2019
- Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief
January 9, 2019
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…